Self-paid health examination: An evidence-based perspective

Journal of Internal Medicine of Taiwan

Volumn 20, Issue 6, 2009, Pages 532-543

  Tseng, Ping Huei ^a   Lin, Hung Ju ^a   Chiu, Han Mo ^a   Lee, Bai Chin ^a   Wu, Ming Shiang ^a   Chen, Ming Fong ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CA 19-9 ANTIGEN; FLUORODEOXYGLUCOSE F 18; PEPSINOGEN I; TUMOR MARKER;

CANCER SCREENING; CARDIOVASCULAR DISEASE; CHROMOENDOSCOPY; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; EVIDENCE BASED PRACTICE; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; MEDICAL EXAMINATION; METHODOLOGY; PREVALENCE; REVIEW; SCREENING; SCREENING TEST; SELF CARE; SENSITIVITY AND SPECIFICITY;

EID: 75149159616     PISSN: 10167390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Grimes DA, Schulz KF. Uses and abuses of screening tests. Lancet 2002; 359: 881-4.
2. Guide to Clinical Preventive Services, Recommendations of the U.S. Preventive Services Task Force, 2008, http://www. ahrq.gov/clinic/pocketgd08/.
3. Chinese source
4. Chinese source
5. Provenzale D, Gray RN. Colorectal cancer screening and treatment: review of outcomes research. J Natl Cancer Inst Monogr 2004: 45-55.
6. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-32.
7. Chiu HM, Wang HP, Lee YC, et al. A prospective study of the frequency and the topographical distribution of colon neoplasia in asymptomatic average-risk Chinese adults as determined by colonoscopic screening. Gastrointest Endosc 2005; 61: 547-53.
8. Chiu HM, Lin JT, Shun CT, et al. Association of metabolic syndrome with proximal and synchronous colorectal neoplasm. Clin Gastroenterol Hepatol 2007; 5: 221-9; quiz 141.
9. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993; 329: 1977-81.
10. James RM, Cruickshank ME, Siddiqui N. Management of cervical cancer: summary of SIGN guidelines. BMJ 2008; 336: 41-3.
11. Chen CA, Hsieh CY. Recent advances and problems in primary therapy for cervical cancer in Taiwan. J Formos Med Assoc 2004; 103: 511-8.
12. Koong SL, Yen AM, Chen TH. Efficacy and cost-effectiveness of nationwide cervical cancer screening in Taiwan. J Med Screen 2006; 13 (Suppl 1): S44-7.
13. Lin YJ, Chen CS, Liu TC, Lin HC. Taiwan's national health insurance system and the application of preventive care: the case of Pap smear testing. Public Health 2008; 122: 857-61.
14. Pasternak RC, Abrams J, Greenland P, Smaha LA, Wilson PW, Houston-Miller N. 34th Bethesda Conference: Task force #1-Identification of coronary heart disease risk: is there a detection gap? J Am Coll Cardiol 2003; 41: 1863-74.
15. Chiu HM, Lin JT, Wang HP, Lee YC, Wu MS. The impact of colon preparation timing on colonoscopic detection of colorectal neoplasms-a prospective endoscopist-blinded randomized trial. Am J Gastroenterol 2006; 101: 2719-25.
16. Sawaya GF, Grimes DA. New technologies in cervical cytology screening: a word of caution. Obstet Gynecol 1999; 94: 307-10.
17. Einstein AJ, Henzlova MJ, Rajagopalan S. Estimating risk of cancer associated with radiation exposure from 64-slice computed tomography coronary angiography. JAMA 2007; 298: 317-23.
18. Einstein AJ, Sanz J, Dellegrottaglie S, et al. Radiation dose and cancer risk estimates in 16-slice computed tomography coronary angiography. J Nucl Cardiol 2008; 15: 232-40.
19. Oyelese AO, Asuzu MC, Osoba AO. Pattern of reactive serological tests for syphilis in different population groups attending the University College Hospital Ibadan (1976-1985). Afr J Med Med Sci 1990; 19: 163-6.
20. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999; 91: 434-7.
21. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149: 638-58.
22. Tseng PH, Lee YC, Chiu HM, et al. Prevalence and clinical characteristics of Barrett's esophagus in a Chinese general population. J Clin Gastroenterol 2008; 42: 1074-9.
23. Chang CY, Lee YC, Lee CT, et al. The application of Prague C and M criteria in the diagnosis of Barrett's esophagus in an ethnic Chinese population. Am J Gastroenterol 2009; 104: 13-20.
24. Lee YC, Yen AM, Tai JJ, et al. The effect of metabolic risk factors on the natural course of gastro-oesophageal reflux disease. Gut 2009; 58: 174-81.
25. Leung WK, Wu MS, Kakugawa Y, et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol 2008; 9: 279-87.
26. Lee YC, Lin JT, Wu HM, et al. Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 875-85.
27. Wald N, Cuckle H. Reporting the assessment of screening and diagnostic tests. Br J Obstet Gynaecol 1989; 96: 389-96.
28. Drobatz KJ. Measures of accuracy and performance of diagnostic tests. J Vet Cardiol 2009; 11 (Suppl) 1: S33-40.
29. Lee YC, Lin JT, Wang HP, Chiu HM, Wu MS. Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease. J Gastroenterol Hepatol 2007; 22: 1286-92.
30. Fu KI, Sano Y, Kato S, et al. Chromoendoscopy using indigo carmine dye spraying with magnifying observation is the most reliable method for differential diagnosis between non-neoplastic and neoplastic colorectal lesions: a prospective study. Endoscopy 2004; 36: 1089-93.
31. Chiu HM, Chang CY, Chen CC, et al. A prospective comparative study of narrow-band imaging, chromoendoscopy, and conventional colonoscopy in the diagnosis of colorectal neoplasia. Gut 2007; 56: 373-9.
32. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007; 115: 459-67.
33. Lauer M, Froelicher ES, Williams M, Kligfield P. Exercise testing in asymptomatic adults: a statement for professionals from the American Heart Association Council on Clinical Cardiology, Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation 2005; 112: 771-6.
34. Taylor AJ, Bindeman J, Feuerstein I, Cao F, Brazaitis M, O'Malley PG. Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors: mean three-year outcomes in the Prospective Army Coronary Calcium (PACC) project. J Am Coll Cardiol 2005; 46: 807-14.
35. Gottlieb I, Lima JA. Screening high-risk patients with computed tomography angiography. Circulation 2008; 117: 1318-32; discussion 32.
36. Mowatt G, Cummins E, Waugh N, et al. Systematic review of the clinical effectiveness and cost-effectiveness of 64-slice or higher computed tomography angiography as an alternative to invasive coronary angiography in the investigation of coronary artery disease. Health Technol Assess 2008; 12: iii-iv, ix-143.
37. Isles MG, McConkey C, Mehanna HM. A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol 2008; 33: 210-22.
38. Minamimoto R, Senda M, Uno K, et al. Performance profile of FDG-PET and PET/CT for cancer screening on the basis of a Japanese Nationwide Survey. Ann Nucl Med 2007; 21: 481-98.
39. Chen YK, Ding HJ, Su CT, et al. Application of PET and PEt/CT imaging for cancer screening. Anticancer Res 2004; 24: 4103-8.
40. Otsuka H, Morita N, Yamashita K, Nishitani H. FDG-PET/ CT for cancer management. J Med Invest 2007; 54: 195-9.
41. Ghotbi N, Iwanaga M, Ohtsuru A, Ogawa Y, Yamashita S. Cancer screening with whole-body PET/CT for healthy asymptomatic people in Japan: re-evaluation of its test validity and radiation exposure. Asian Pac J Cancer Prev 2007; 8: 93-7.
42. Petersen RP, Harpole DH, Jr. Computed tomography screening for the early detection of lung cancer. J Natl Compr Canc Netw 2006; 4: 591-4.
43. McWilliams A, Mayo J. Computed tomography-detected noncalcified pulmonary nodules: a review of evidence for significance and management. Proc Am Thorac Soc 2008; 5: 900-4.
44. Sone S, Takashima S, Li F, et al. Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet 1998; 351: 1242-5.
45. Lopes Pegna A, Picozzi G, Mascalchi M, et al. Design, recruitment and baseline results of the ITALUNG trial for lung cancer screening with low-dose CT. Lung Cancer 2009; 64: 34-40.
46. Bach PB, Niewoehner DE, Black WC. Screening for lung cancer: the guidelines. Chest 2003; 123: 83S-8S.
47. Duffy MJ, van Dalen A, Haglund C, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007; 43: 1348-60.
48. Macdonald JS. Carcinoembryonic antigen screening: pros and cons. Semin Oncol 1999; 26: 556-60.
49. Meeker WR, Jr. The use and abuse of CEA test in clinical practice. Cancer 1978; 41: 854-62.
50. Chevinsky AH. CEA in tumors of other than colorectal origin. Semin Surg Oncol 1991; 7: 162-6.
51. Sheu JC, Sung JL, Chen DS, et al. Early detection of hepatocellular carcinoma by real-time ultrasonography. A prospective study. Cancer 1985; 56: 660-6.
52. Chen CJ, Lu SN, You SL, et al. [Community-based hepatocellular carcinoma screening in seven townships in Taiwan]. J Formos Med Assoc 1995; 94 (Suppl 2): S94-102.
53. Chen TH, Chen CJ, Yen MF, et al. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a High risk group in Taiwan. Int J Cancer 2002; 98: 257-61.
54. Chang CY, Huang SP, Chiu HM, Lee YC, Chen MF, Lin JT. Low efficacy of serum levels of CA 19-9 in prediction of malignant diseases in asymptomatic population in Taiwan. Hepatogastroenterology 2006; 53: 1-4.
55. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-61.
56. Lin K, Lipsitz R, Miller T, Janakiraman S. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149: 192-9.
57. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8.
58. Andriole GL, Crawford ED, Grubb RL, 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-9.
59. Bates SE, Longo DL. Tumor markers: value and limitations in the management of cancer patients. Cancer Treat Rev 1985; 12: 163-207.
60. Lowhagen GB. Syphilis: test procedures and therapeutic strategies. Semin Dermatol 1990; 9: 152-9.
61. Gauthier DK, Turner JG. Anti-HIV antibody testing: procedures and precautions. Am J Infect Control 1989; 17: 213-25.
62. Gurtler L. Difficulties and strategies of HIV diagnosis. Lancet 1996; 348: 176-9.
63. Lu SN, Wang JH, Liu SL, et al. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer 2006; 107: 2212-22.
64. Lu SN, Wang JH, Chen PF, et al. Community-based mass ultrasonographic screening of hepatocellular carcinoma among thrombocytopenic adults. Cancer Epidemiol Biomarkers Prev 2008; 17: 1813-21.
65. Niederau C, Grendell JH. Diagnosis of pancreatic carcinoma. Imaging techniques and tumor markers. Pancreas 1992; 7: 66-86.
66. Pleskow DK, Berger HJ, Gyves J, Allen E, McLean A, Podolsky DK. Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med 1989; 110: 704-9.
67. Riker A, Libutti SK, Bartlett DL. Advances in the early detection, diagnosis, and staging of pancreatic cancer. Surg Oncol 1997; 6: 157-69.
68. Lee YC, Wang CP, Chen CC, et al. Transnasal endoscopy with narrow-band imaging and Lugol staining to screen patients with head and neck cancer whose condition limits oral intubation with standard endoscope (with video). Gastrointest Endosc 2009; 69: 408-17.
69. Duffy SW, Nagtegaal ID, Wallis M, et al. Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival. Am J Epidemiol 2008; 168: 98-104.
70. Hou MF, Chuang HY, Ou-Yang F, et al. Comparison of breast mammography, sonography and physical examination for screening women at high risk of breast cancer in taiwan. Ultrasound Med Biol 2002; 28: 415-20.